Organon & Co. (OGN)
| Market Cap | 1.73B |
| Revenue (ttm) | 6.28B |
| Net Income (ttm) | 700.00M |
| Shares Out | 259.97M |
| EPS (ttm) | 2.69 |
| PE Ratio | 2.48 |
| Forward PE | 1.75 |
| Dividend | $0.08 (1.13%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 20,517,748 |
| Open | 7.05 |
| Previous Close | 7.06 |
| Day's Range | 6.39 - 7.05 |
| 52-Week Range | 6.39 - 19.05 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 17.33 (+160.21%) |
| Earnings Date | Oct 30, 2025 |
About OGN
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]
Financial Performance
In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OGN stock is "Buy." The 12-month stock price target is $17.33, which is an increase of 160.21% from the latest price.
News
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 p...
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings...
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices
Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplano...
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufa...
Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy
Organon remains a buy as the stock trades at distressed valuations despite stable fundamentals and progress on debt reduction. OGN's Women's Health and Biosimilars segments drive growth, offsetting re...
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
Organon: Valuation Discount Offset By Structural Headwinds
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines...
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new produc...
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of R...
Organon Reports Results for the Second Quarter Ended June 30, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to report second quarter 2025 results and host conference call on August 5, 2025.
OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal s...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company'...
Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's steroid-free VTAMA (tapinarof) cream 1%, granted strong recommendation in American Academy of Dermatology guidelines for atopic dermatitis.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquire...
Karolinska Development receives update from Organon concerning OG-6219
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon throug...
Organon to halt development of endometriosis pain drug after mid-stage trial failure
Organon said on Wednesday it will discontinue the development of its experimental drug, after it failed to reduce pain in women suffering from endometriosis in a mid-stage study.
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the invest...
OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company'...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN
NEW YORK , June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period l...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN
NEW YORK , June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period l...